CompletedPhase 4

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

United States500 participantsStarted 2001-10

Plain-language summary

Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria * Signed informed consent * Greater than 18 years of age * Proof of breast cancer, multiple myeloma or prostate cancer * Diagnosis of at least one cancer-related bone lesion * If patient is of child-bearing potential, negative pregnancy test and on a medically recognized form of contraception * ECOG performance status of 0,1 or 2 * Ability to read, understand and write English or Spanish language * Normal renal function * Corrected serum calcium equal to or greater than 8mg/dl Exclusion Criteria * clinically symptomatic brain metastases * hypersensitivity to Zometa or other bisphosphonates * pregnant or lactating

What they're measuring

Pain score assessed by change from baseline

Trial details

NCT IDNCT00029224

SponsorNovartis

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2002-11

View on ClinicalTrials.gov More Breast Cancer trials